IL‐1RA suppresses esophageal cancer cell growth by blocking IL‐1α

Chen, Sui; Shen, Zhimin; Liu, Zhun; Gao, Lei; Han, Ziyang; Yu, Shaohua; Kang, Myounggu

doi:10.1002/jcla.22903

Cited by 19 publications

(15 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-1 is involved in promoting angiogenesis through the production of vascular endothelial growth factor (VEGF) [ 73 ]. The downregulated expression of IL-1 receptor antagonist (IL-1RA) in EC is associated with tumor progression and poor survival [ 74 ]. Overexpression of IL-1RA in IL-1α expressing KYSE410 EC cells decreased proliferation and reduced expression of VEGF-A [ 74 ].…”

Section: Cytokine/chemokine Expression In Esophageal Cancermentioning

confidence: 99%

“…The downregulated expression of IL-1 receptor antagonist (IL-1RA) in EC is associated with tumor progression and poor survival [ 74 ]. Overexpression of IL-1RA in IL-1α expressing KYSE410 EC cells decreased proliferation and reduced expression of VEGF-A [ 74 ]. On the contrary, no effect of IL-1RA overexpression was observed in EC9706 cells (low IL-1α expression) proliferation and VEGF-A expression [ 74 ].…”

Section: Cytokine/chemokine Expression In Esophageal Cancermentioning

confidence: 99%

“…Overexpression of IL-1RA in IL-1α expressing KYSE410 EC cells decreased proliferation and reduced expression of VEGF-A [ 74 ]. On the contrary, no effect of IL-1RA overexpression was observed in EC9706 cells (low IL-1α expression) proliferation and VEGF-A expression [ 74 ]. IL-1β is a pro-inflammatory cytokine which is highly expressed in EC tissues and promotes invasion and migration [ 75 ].…”

Section: Cytokine/chemokine Expression In Esophageal Cancermentioning

confidence: 99%

“…Treatment of EC cell lines with caffeic acid phenethyl ester, a specific inhibitor of NF–κB, inhibited cell migration and invasion in vitro, and reduced tumor growth in vivo [ 70 ]. Several studies have shown that IL-1RA expression is significantly lower in ESCC patients’ samples [ 74 , 217 ] than adjacent normal tissues. The reduced expression of IL-1RA correlated with advanced clinical staging of the tumor, decreased 5-year survival, and poor clinical outcome.…”

Section: Targeting Cytokine/ Chemokine Network In Esophageal Cancermentioning

confidence: 99%

See 3 more Smart Citations

Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy

et al. 2021

View full text Add to dashboard Cite

Esophageal cancer (EC) is a disease often marked by aggressive growth and poor prognosis. Lack of targeted therapies, resistance to chemoradiation therapy, and distant metastases among patients with advanced disease account for the high mortality rate. The tumor microenvironment (TME) contains several cell types, including fibroblasts, immune cells, adipocytes, stromal proteins, and growth factors, which play a significant role in supporting the growth and aggressive behavior of cancer cells. The complex and dynamic interactions of the secreted cytokines, chemokines, growth factors, and their receptors mediate chronic inflammation and immunosuppressive TME favoring tumor progression, metastasis, and decreased response to therapy. The molecular changes in the TME are used as biological markers for diagnosis, prognosis, and response to treatment in patients. This review highlighted the novel insights into the understanding and functional impact of deregulated cytokines and chemokines in imparting aggressive EC, stressing the nature and therapeutic consequences of the cytokine-chemokine network. We also discuss cytokine-chemokine oncogenic potential by contributing to the Epithelial-Mesenchymal Transition (EMT), angiogenesis, immunosuppression, metastatic niche, and therapeutic resistance development. In addition, it discusses the wide range of changes and intracellular signaling pathways that occur in the TME. Overall, this is a relatively unexplored field that could provide crucial insights into tumor immunology and encourage the effective application of modulatory cytokine-chemokine therapy to EC.

show abstract

Section: Cytokine/chemokine Expression In Esophageal Cancermentioning

confidence: 99%

Section: Cytokine/chemokine Expression In Esophageal Cancermentioning

confidence: 99%

Section: Cytokine/chemokine Expression In Esophageal Cancermentioning

confidence: 99%

Section: Targeting Cytokine/ Chemokine Network In Esophageal Cancermentioning

confidence: 99%

See 2 more Smart Citations

Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Some studies found that IL-1ra was a competitive inhibitor of IL-1(α/β) [49] and was neuroprotective in the mice that had a stroke [50]. IL-1ra could also suppress the growth of esophageal cancer cells by blocking IL-1α [51]. In this article, IL-1ra could play a crucial role because it was clearly related with MDSCs and CD68 + CD163 + M2-like macrophages in NSCLC patients in RT, which deserved deep investigations in the following experiments.…”

Section: Discussionmentioning

confidence: 99%

Dynamic alterations of myeloid-derived suppressor cells and CD68+CD163+M2-like macrophages of non-small cell lung cancer patients in radiotherapy

Zhuang

Shao

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundRecent studies showed that myeloid-derived suppressor cells (MDSCs) and M2-like macrophages are involved in the treatment of non-small cell lung cancer (NSCLC) as immunosuppressive cells; however, the changes of MDSCs and M2-like macrophages, and their prognostic value are rarely unknown in NSCLC patients during radiotherapy. In this article, we aim to explore dynamic alteration of the circulating MDSCs and M2-like macrophages, to examine their relationship, and to evaluate their prognostic value for NSCLC patients in radiotherapy.Method:Peripheral blood mononuclear cells from healthy controls and NSCLC patients in radiotherapy were isolated to examine the circulating MDSCs and M2-like macrophages. The peripheral MDSCs defined as CD11b+CD33+HLA-DR− and M2-like Macrophages signified as CD68+CD163+ were determined by flow cytometry. 40 plasma inflammatory cytokines were measured by multiplex ELISA.ResultsCompared with health controls, the percentages of MDSCs and CD68+CD163+M2-like macrophages of NSCLC patients were significantly elevated, and were distinctly higher in NSCLC patients in radiotherapy than in pre-radiotherapy. Moreover, MDSCs correlated positively with CD68+CD163+M2-like macrophages in NSCLC patients in radiotherapy and post-radiotherapy. Interestingly, the alterations of the percentages of MDSCs and CD68+CD163+M2-like macrophages in RT were irrelated with radiotherapy area. During radiotherapy, the proportions of MDSCs were clearly increased in adenocarcinoma patients but not in squamous carcinoma patients, while the proportions of CD68+CD163+M2-like macrophages were markedly elevated in squamous carcinoma patients but not in adenocarcinoma patients. In addition, the percentages of MDSCs and CD68+CD163+ M2-like macrophages were also increased in NSCLC patients reached PR in radiotherapy compared to NSCLC patients reached SD and PD. IL-1ra and MIP-1β have a positive relation with MDSCs or M2 macrophages in NSCLC patients in radiotherapy, and Eotaxin was correlated with CD68+CD163+M2-like macrophages but not MDSCs in NSCLC patients after radiotherapy.ConclusionsThe dynamic alterations of MDSCs and M2-like macrophages, as well as their connection with plasm inflammation cytokines, could provide potentially prognostic and sensitive markers for NSCLC patients in radiotherapy.Trial Registration: Jinshan Hospital of Fudan University, IEC-2020-S01. Registered 22 May 2020.

show abstract

Strontium and antimony serum levels in healthy individuals living in high‐ and low‐risk areas of esophageal cancer

Mirzaee

Semnani

Roshandel

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background It has been shown there is an upward trend for strontium (Sr) and antimony (Sb) levels from low‐risk (LR) to high‐risk (HR) areas of etiology of esophageal cancer in water, soil, and grains grown in Golestan province. In the present study, the serum levels of Sr and Sb were determined in healthy individuals living in these areas. Methods This cross‐sectional study was performed on fasting blood serum of adult healthy individuals collected by cluster sampling. Subjects were divided into two groups, those living in either HR or LR areas. Strontium and antimony serum levels were measured using a graphite furnace atomic absorption spectroscopy. Results A total of 200 volunteers were enrolled from which 96 persons (48%) and 104 persons (52%) were from either HR or LR areas, respectively. The sex distribution was 40.9% male and 59.1% female, and the average age of enrolled people was 50.9 years. The average strontium levels were 30.44 ± 4.05 and 30.29 ± 3.74 μg/L in LR and HR, respectively. It also has been shown the average antimony levels were 15.21 ± 3.40, 14.81 ± 3.17, 15.13 ± 3.62, and 15.07 ± 3.62 μg/L in LR, HR, urban, and rural populations, respectively. Conclusion The serum levels of strontium and antimony were not significantly different in healthy adults living in high‐ and low‐risk areas of esophageal cancer. However, the average antimony serum levels in Golestan Province were above the reference interval in different countries.

show abstract

IL‐1RA suppresses esophageal cancer cell growth by blocking IL‐1α

Cited by 19 publications

References 24 publications

Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy

Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy

Dynamic alterations of myeloid-derived suppressor cells and CD68+CD163+M2-like macrophages of non-small cell lung cancer patients in radiotherapy

Strontium and antimony serum levels in healthy individuals living in high‐ and low‐risk areas of esophageal cancer

Contact Info

Product

Resources

About